Skip to main content
Premium Trial:

Request an Annual Quote

Weber Named VP, Senior Marketing at Stratagene; Colpan Joins Board of Genpat77; Grint Joins Board at Illumina; Herbert Promoted to CFO of Pressure Biosciences; and others



David Weber has been named senior vice president of marketing at Stratagene, the company said this week. Weber will lead the La Jolla, Calif.-based company's global marketing programs for its life sciences division.


Weber was most recently president, Region Americas of for GE Healthcare. He also spent 17 years at Pharmacia Biotech, Amersham Pharmacia Biotech, and Amersham Biosciences. He holds a BS in biochemistry from RutgersUniversity.


Metin Colpan this week was appointed to the supervisory board of Genpat77, the Berlin-based company said.


Colpan co-founded and was CEO of Qiagen until the end of 2003. He has remained at Qiagen as senior technology advisor and member of its supervisory board. Prior to founding Qiagen, Colpan was an investigator at the Institute for Biophysics at the University of Dusseldorf, Germany.


Colpan sits on the boards of several companies, including GPC Biotech, Morphosys and Ingenium. He earned his PhD and MS in organic chemistry and chemical engineering from the Darmstadt Institute of Technology, Germany, in 1983.


Paul Grint has joined Illumina's board of directors, the San Diego-based company announced this week.


Grint is currently senior vice president and chief medical officer of Zephyr Sciences, a biopharmaceutical company. Prior to joining Zephyr, Grint was vice president and head of clinical R&D for Pfizer in La Jolla, Calif. He previously held administrative positions at IDEC Pharmaceuticals, Schering-Plough and Wellcome Research Laboratories.


Grint received his medical degree from the Universityof London, St. Bartholomew's HospitalMedicalCollege in London, UK.


He replaces Scott Greer, an Illumina board member since May 2001 and the chairman of Abigenics, who resigned on Tuesday.  


Pressure Biosciences this week appointed Steven Herbert as chief financial officer, vice president of finance, and assistant treasurer.


Herbert had been a part-time financial consultant to the Westborough, Mass.-based biotech.  He previously had served as vice president of finance & corporate controller for Brooks Automation. Herbert also held senior administrative positions at Whistler Corporation, the Foxboro Company, Augat, and Data General. He earned both his BA and his MA in accounting from BryantCollege.


In addition, Pressure Biosciences also appointed Jose Lanuza as director of sales.

Lanuza previously served as a senior sales executive for Cliniqa, Medical Analysis Systems, Serono, Hybritech, and Abbott Laboratories.


Robert Negm has become the new vice president of business development at GenTel BioSurfaces. Prior to joining GenTel, Negm was director of business development at Whatman, Schleicher & Schuell for two years. Prior to that, he was a program director at the National Cancer Institute.


Galapagos this week appointed Andre Hoekema managing director of Galadeno, the services unit for the Dutch genomics-based drug discovery company.


Prior to joining Galapagos, Hoekema served as the managing director of corporate development Europe for Invitrogen. He previously held positions at Molecular Probes Europe, Crucell, DSM Life Sciences, and Genentech.


Hoekema holds a PhD in physics and mathematics from LeidenUniversity.

Hitachithis week appointed David Skiados as its USA director of sales for its High Technologies America subsidiary, the company said.


Prior to joining Hitachi HTA, Skiados held sales and business development positions at MWG Biotech, Ionics, and PerkinElmer/ABI. Skiados also served as a senior staff scientist at the National Institute of Allergy and

Infectious Diseases, according to Hitachi.


Craig Mello, chairman of molecular medicine at the Universityof Massachusetts MedicalSchool, was one of six scientists named as winners of the Gairdner International awards announced this month.

Other winners included: Douglas Coleman, senior staff scientist, emeritus, of the Jackson Lab of Bar Harbor, Maine; Jeffrey Friedman of The Rockefeller University of New York and director of the Staff Center for Human Genetics; Andrew Fire, professor of pathology and genetics at Stanford University School of Medicine; Brenda Milner, professor of cognitive neuroscience, Montreal Neurological Institute of McGill University in Montreal; and Endel Tulving, chairman of cognitive neuroscience, Rotman Research Institute, University of Toronto.


Bruce Kimmel this week was named vice president, therapeutic applications for Ambrx, the San Diego-based biopharmaceutical company said.


Kimmel previously held administrative positions at Diversa and Amgen. He served as the director of the Drosophila Genome Project at Lawrence Berkeley National Laboratories. Kimmel holds a PhD in biochemistry from the Universityof California, Berkeley.


Lewis Cantley, an investigator at Beth Israel Deaconess Medical Center has received the eighth annual Pezcoller Foundation-American Association of Cancer Research International Award for Cancer Research.


The award honors a scientist who has made a major scientific discovery in either basic or translational cancer research. This year's prize recognizes Cantley for his leadership in the field of signal transduction.


Cantley is the chief of the division of signal transduction at BIDMC and professor of systems biology at Harvard Medical School. Cantley joined the faculty of BIDMC in 1992, and previously held positions at Tufts University School of Medicine.


He is a graduate of West Virginia Wesleyan College, and holds a doctorate in biophysical chemistry from CornellUniversity.


Iuliana Lazar, a research assistant professor at the Virginia Bioinformatics Institute at 

Virginia Polytechnic Institute, this week was awarded a five-year, $400,000 National Science Foundation Faculty Early Career Development Award for research on the development of microfluidic devices with mass spectrometric detection for proteomic applications.


This research will lead to the development of unique micro-analytical systems and detection strategies that can be used in the areas of biomedical research, medicine, agriculture, biodefense, and other areas that benefit from proteomic investigations, according to Virginia Tech.


The long-term objective of Lazar's project is the development of microfluidic platforms with mass spectrometric detection for bioanalytical applications. Three areas of research will be examined: microfluidic platform development, microchip-mass spectrometric interface development, and bioanalytical process implementation on the chip.


Lazar received her PhD in chemistry at Brigham Young University in 1997. Before joining VBI in 2003, she spent two years as a postdoctoral fellow at Oak Ridge National Laboratory and three years as a principal research scientist at the Barnett Institute at NortheasternUniversity.


Bryan Koontz has been named senior vice president and general manager of discovery informatics at Tripos, the St. Louis-based company said this week


Koontz joined Tripos as vice president of marketing and corporate development in January when Tripos acquired Optive Research, where he was serving as CEO. Koontz co-founded Optive, a discovery informatics software company, as a technology spin off from the Universityof Texas, Austin in 2002.


Koontz holds a BS in mechanical engineering with a minor in engineering mechanics from Pennsylvania State University and a MS in mechanical engineering from Massachusetts Institute of Technology.


He succeeds Trevor Heritage, who is leaving Tripos to pursue other interests.


Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.